Details

Autor(en) / Beteiligte

• Schaid, Daniel J.
• McDonnell, Shannon K.
• FitzGerald, Liesel M.
• DeRycke, Lissa
• Fogarty, Zachary
• Giles, Graham G.
• MacInnis, Robert J.
• Southey, Melissa C.
• Nguyen-Dumont, Tu
• Cancel-Tassin, Geraldine
• Cussenot, Oliver
• Whittemore, Alice S.
• Sieh, Weiva
• Ioannidis, Nilah Monnier
• Hsieh, Chih-Lin
• Stanford, Janet L.
• Schleutker, Johanna
• Cropp, Cheryl D.
• Carpten, John
• Hoegel, Josef
• Eeles, Rosalind
• Kote-Jarai, Zsofia
• Ackerman, Michael J.
• Klein, Christopher J.
• Mandal, Diptasri
• Cooney, Kathleen A.
• Bailey-Wilson, Joan E.
• Helfand, Brian
• Catalona, William J.
• Wiklund, Fredrick
• Riska, Shaun
• Bahetti, Saurabh
• Larson, Melissa C.
• Cannon Albright, Lisa
• Teerlink, Craig
• Xu, Jianfeng
• Isaacs, William
• Ostrander, Elaine A.
• Thibodeau, Stephen N.

Titel

Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer

Ist Teil von

• European urology, 2021-03, Vol.79 (3), p.353-361

Ort / Verlag

Switzerland: Elsevier B.V

Erscheinungsjahr

2021

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Family history of prostate cancer (PCa) is a well-known risk factor, and both common and rare genetic variants are associated with the disease. To detect new genetic variants associated with PCa, capitalizing on the role of family history and more aggressive PCa. A two-stage design was used. In stage one, whole-exome sequencing was used to identify potential risk alleles among affected men with a strong family history of disease or with more aggressive disease (491 cases and 429 controls). Aggressive disease was based on a sum of scores for Gleason score, node status, metastasis, tumor stage, prostate-specific antigen at diagnosis, systemic recurrence, and time to PCa death. Genes identified in stage one were screened in stage two using a custom-capture design in an independent set of 2917 cases and 1899 controls. Frequencies of genetic variants (singly or jointly in a gene) were compared between cases and controls. Eleven genes previously reported to be associated with PCa were detected (ATM, BRCA2, HOXB13, FAM111A, EMSY, HNF1B, KLK3, MSMB, PCAT1, PRSS3, and TERT), as well as an additional 10 novel genes (PABPC1, QK1, FAM114A1, MUC6, MYCBP2, RAPGEF4, RNASEH2B, ULK4, XPO7, and THAP3). Of these 10 novel genes, all but PABPC1 and ULK4 were primarily associated with the risk of aggressive PCa. Our approach demonstrates the advantage of gene sequencing in the search for genetic variants associated with PCa and the benefits of sampling patients with a strong family history of disease or an aggressive form of disease. Multiple genes are associated with prostate cancer (PCa) among men with a strong family history of this disease or among men with an aggressive form of PCa. Family history of prostate cancer (PCa) is a well-known risk factor. By capitalizing on affected men with a strong family history of disease or with more aggressive disease, we identified 10 novel genes, with eight of these primarily associated with aggressive PCa.